Meeting
2016 ASCO Annual Meeting
A cancer precision medicine platform for multiple simultaneous genomic assays from metastatic biopsies (bx) in ER+ metastatic breast cancer.
Authors
Nikhil Wagle
Dana-Farber Cancer Institute, Boston, MA
Nikhil Wagle , Karla Helvie , Maxwell R. Lloyd , Lori Marini , Adrienne Gropper Waks , Ofir Cohen , Coyin Oh , Carrie Sougnez , Nelly Oliver , Qaren Quartey , Asaf Rotem , Parin Shah , Neal Ian Lindeman , Ian E. Krop , Levi A. Garraway , Eric P. Winer , Nancy U. Lin
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Tumor Biology
Track
Tumor Biology
Sub Track
Tumor-Based Biomarkers
Citation
J Clin Oncol 34, 2016 (suppl; abstr 11513)
DOI
10.1200/JCO.2016.34.15_suppl.11513
Abstract #
11513
Poster Bd #
210
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
ESR1 mutational landscape and impact of co-existing resistance variants on clinical outcomes in patients with metastatic breast cancer.
First Author: Arielle J Medford
Poster
2019 ASCO Annual Meeting
Next-generation sequencing (NGS) results among hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (MBC) patients treated with a CDK4 & 6 inhibitor: A retrospective observational study based on real‑world data.
First Author: Erika Paige Hamilton
Poster
2022 ASCO Annual Meeting
Defining resistance mechanisms to CDK4/6 inhibition in hormone receptor-positive HER2-negative metastatic breast cancer (MBC) through a machine learning approach applied to circulating tumor DNA (ctDNA).
First Author: Lorenzo Gerratana
Poster
2020 ASCO Virtual Scientific Program
Acquired genomic alterations in circulating tumor DNA from patients receiving abemaciclib alone or in combination with endocrine therapy.
First Author: Matthew P. Goetz